ESR1 and breast carcinoma: Studies have shown that there is no effect on breast cancer outcome on women with ER negative receptors when exposed to tamoxifen, whereas using of tamoxifen for more than 10 years in ER positive women with breast cancer leads to reduced recurrence and mortality [22].